icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
fNwhVnkKtKQdQWL9
Listen
